Wang, P., Chen, Y., Wang, F., Chen, M., Zheng, B., Zhang, D., Zheng, Q., Wang, J., Chen, J., Cai, H., Liu, J., Zhang, W., Lian, C., Chen, J., Lin, Y., Xu, Y., Huang, R., Lei, M., Chen, P., He, H., Lin, H., Chen, X., Zhou, H., Chen, W., Wei, W., Zhuang, F., Lin, J., Huang, C., Guan, N., Yan, J., Liang, S., Liu, S., Li, J. (2025). Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO). Nature Communications. https://doi.org/10.1038/s41467-025-64660-z